Guard Therapeutics have announced that 134 of the planned 268 patients have been dosed in the global randomized, double-blinded and placebo-controlled Phase 2 clinical trial (AKITA).
The AKITA study has been designed to evaluate the kidney-protective effects of the investigational drug RMC-035 in